Basic Study
Copyright ©The Author(s) 2022.
World J Orthop. Jun 18, 2022; 13(6): 587-602
Published online Jun 18, 2022. doi: 10.5312/wjo.v13.i6.587
Table 1 The main characteristics of the platelet-rich plasma protocols used in the study

Arthrex ACP
Mini GPS III
Xerthra
Dr. PRP
Amount of blood collected 13.5 mL27 mL13.5 mL18 mL
Final amount of PRP4 mL3 mL1.5 mL3 mL
Drawn blood/obtained PRP3.38:19:19:16:1
Anticoagulant typeACD-AACD-A3.13% SOD CITR3.13% SOD CITR
Anticoagulant amount1.5 mL3 mL1.5 mL2 mL
Number of spins1111
RPM1500320035003100
Centrifugation time5’15’5’4’
Removal of PPPnoyesyesyes
Expected WBC contentlowhigh, 5xlowlow
Expected PLT concentration2-3 x9.3 x2-13 x4-5 x
Dedicated centrifugeYesYesYesYes
Activation methodIn vivoIn vivoIn vivoIn vivo
Type of PRPConditioned PlasmaLR-PRPLP-PRPLP-PRP
Table 2 Whole blood count with differential leukocyte of all participants
Differential leukocyteBlood count
RBC (1012/L)4.97 ± 0.43
PLT (109/L)240.67 ± 49.85
WBC (109/L)6.49 ± 1.49
Neutrophils (109/L)3.79 ± 1.29
Lymphocytes (109/L)2.08 ± 0.45
Monocytes (109/L)0.45 ± 0.13
Eosinophils (109/L)0.14 ± 0.08
Basophils (109/L)0.04 ± 0.01
Table 3 Concentrations of blood cell components in platelet-rich plasma samples

Arthrex ACP
Mini GPS III
Xerthra
Dr. PRP
PLT (109/L)357.33 ± 99.011212.67 ± 268.63455.27 ± 362.92499.75 ± 153.46
WBC (109/L)0.87 ± 1.0134.19 ± 11.181.80 ± 2.550.60 ± 0.87
Neutrophils (109/L)0.87 ± 1.0116.71 ± 9.891.80 ± 2.550.60 ± 0.87
RBC (1012/L)0.05 ± 0.081.49 ± 0.860.02 ± 0.020.01 ± 0.01
xPLT1.47 ± 0.185.05 ± 0.671.96 ± 1.712.14 ± 0.73
xWBC0.14 ± 0.175.27 ± 1.410.29 ± 0.40.10 ± 0.16
xRBC0.01 ± 0.020.30 ± 0.170.000.00
Table 4 The coefficient of variation in the concentration of blood cell components for different platelet-rich plasma preparation systems

WBC
RBC
PLT
Arthrex ACP [%]114.80175.6912.18
Mini GPS III [%]26.7956.8313.25
Xerthra [%]149.38133.9895.95
Dr. PRP [%]151.4595.1034.05